|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:acquisition_year
|
gptkb:2015
|
|
gptkbp:ceo
|
gptkb:Troyen_A._Brennan
|
|
gptkbp:clinical_trial
|
gptkb:Yes
|
|
gptkbp:employees
|
Approximately 500
|
|
gptkbp:focus
|
Chronic gastrointestinal diseases
|
|
gptkbp:founded
|
gptkb:2001
|
|
gptkbp:founder
|
gptkb:Carlo_A._Di_Marco
|
|
gptkbp:headcount
|
500+
|
|
gptkbp:headquarters
|
gptkb:Bridgewater,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Salix Pharmaceuticals
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Troyen_A._Brennan
gptkb:Michael_J._Mc_Gowan
gptkb:David_A._Hager
gptkb:Joseph_C._Papa
gptkb:Robert_A._Ingram
gptkb:John_M._Mc_Gowan
gptkb:Carlo_A._Di_Marco
gptkb:Richard_L._Glickman
|
|
gptkbp:market
|
gptkb:United_States
|
|
gptkbp:partnerships
|
Various healthcare organizations
|
|
gptkbp:previously_known_as
|
gptkb:Salix_Pharmaceuticals,_Ltd.
|
|
gptkbp:products
|
gptkb:Xifaxan
gptkb:Uceris
Apriso
Relistor
|
|
gptkbp:related_products
|
gptkb:Xifaxan
gptkb:Uceris
Apriso
Relistor
|
|
gptkbp:research_and_development
|
gptkb:Yes
|
|
gptkbp:revenue
|
$1 billion (2020)
|
|
gptkbp:specializes_in
|
Gastroenterology
gastroenterology
|
|
gptkbp:subsidiary
|
gptkb:Valeant_Pharmaceuticals_International,_Inc.
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.salix.com
|
|
gptkbp:bfsParent
|
gptkb:Bausch_Health_Companies
gptkb:Valeant_Pharmaceuticals
gptkb:rifaximin
|
|
gptkbp:bfsLayer
|
6
|